A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs

References

• amfAR. (2017). Preventing HIV and Hepatitis C among people who inject drugs: Public funding for syringe services programs makes the difference. Retrieved from www.amfar.org
   Google Scholar
• Bazzi, A. R., Biancarelli, D. L., Childs, E., Drainoni, M.L., Edeza, A., Salhaney, P., & Biello, K.B. (2018). Limited knowledge and mixed interest in pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs. AIDS Patient Care & STDs, 32(12), 529–537. doi: 10.1089/apc.2018.0126
   PubMed Web of Science ®Google Scholar
• Biancarelli, D. L., Biello, K. B., Childs, E., Drainoni, M.L., Salhaney, P., Edeza, A. … Bazzi, A.R. (In Press). Strategies people who inject drugs use to avoid stigma in the healthcare settings. Drugs and Alcohol Dependence.
   Google Scholar
• Biello, K. B., Bazzi, A. R., Mimiaga, M. J., Biancarelli, D. L., Edeza, A., Salhaney, P., & Childs, E. D. M. (2018). Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduction Journal, 15(1), 55. doi:10.1186/s12954-018-0263-5
   PubMed Web of Science ®Google Scholar
• Biello, K. B., Hosek, S., Drucker, M. T., Belzer, M., Mimiaga, M. J., Marrow, E. … Mayer, K. H. (2018). Preferences for injectable PrEP among young U.S. cisgender men and transgender women and men who have sex with men. Archives of Sexual Behavior, 47(7), 2101–2107. doi:10.1007/s10508-017-1049-7
   PubMed Web of Science ®Google Scholar
• Biello, K. B., Mimiaga, M. J., Santostefano, C. M., Novak, D. S., & Mayer, K. H. (2018). MSM at highest risk for HIV acquisition express greatest interest and preference for injectable antiretroviral PrEP compared to daily, oral medication. AIDS and Behavior, 22(4), 1158–1164. doi: 10.1007/s10461-017-1972-6
   PubMed Web of Science ®Google Scholar
• Bradford, J. B., Coleman, S., & Cunningham, W. (2007). HIV system navigation: An emerging model to improve HIV care access. AIDS Patient Care and STDs, 21(s1), S-49–S-58. doi: 10.1089/apc.2007.9987
   Web of Science ®Google Scholar
• Burnett, J. C., Broz, D., Spiller, M. W., Wejnert, C., & Paz-Bailey, G. (2018). HIV infection and HIV-associated behaviors among persons who inject drugs – 20 cities, United States, 2015. Morbidity and Mortality Weekly Report, 67(1), 23–28. doi: 10.15585/mmwr.mm6701a5
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2017). Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update Clinical Practice Guideline. Retrieved from https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf
   Google Scholar
• Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., … Bangkok Tenofovir Study Group. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 381(9883), 2083–2090. doi: 10.1016/S0140-6736(13)61127-7
   PubMed Web of Science ®Google Scholar
• Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). The changing face of heroin use in the United States. JAMA Psychiatry, 71(7), 821–826. doi: 10.1001/jamapsychiatry.2014.366
   PubMed Web of Science ®Google Scholar
• Conrad, C., Bradley, H. M., Broz, D., Buddha, S., Chapman, E. L., Galang, R. R., … Prevention. (2015). Community outbreak of HIV infection linked to injection drug use of oxymorphone – Indiana, 2015. Morbidity and Mortality Weekly Report, 64(16), 443–444. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25928470
   PubMed Web of Science ®Google Scholar
• DeCuir-Gunby, J. T., Marshall, P. L., & McCulloch, A. W. (2011). Developing and using a codebook for the analysis of interview data: An example from a professional development research project. Field Methods, 23(2), 136–155. doi:10.1177/1525822(10388468 doi: 10.1177/1525822X10388468
   Web of Science ®Google Scholar
• Delany-Moretlwe, S., & Hosseinipour, M. (2017). HPTN 084: A phase 3 double blind safety and efficacy study of long-acting injectable cabotegravir compared to daily oral TDF/FTC for pre-exposure prophylaxis in HIV-uninfected women. Retrieved from https://www.hptn.org/sites/default/files/inline-files/HPTN084ProtocolFINALVersion1.0%2C2March2017_0.pdf
   Google Scholar
• De Molina, A. R., Gutiérrez, R., Ramos, M. A., Silva, J. M., Silva, J., Bonilla, F., … Lacal, J. C. (2002). Mutual mistrust in the medical care of drug users: The keys to the “narc” cabinet. Journal of General Internal Medicine, 17(5), 327–333. doi: 10.1046/j.1525-1497.2002.10625.x
   PubMed Web of Science ®Google Scholar
• Escudero, D. J., Lurie, M. N., Kerr, T., Howe, C. J., & Marshall, B. D. (2014). HIV pre-exposure prophylaxis for people who inject drugs: A review of current results and an agenda for future research. Journal of the International AIDS Society, 17, 18899. doi: 10.7448/IAS.17.1.18899
   PubMed Web of Science ®Google Scholar
• Hall, H. I., Gray, K. M., Tang, T., Li, J., Shouse, L., & Mermin, J. (2012). Retention in care of adults and adolescents living with HIV in 13 US areas. JAIDS Journal of Acquired Immune Deficiency Syndromes, 60(1), 77–82. doi: 10.1097/QAI.0b013e318249fe90
   PubMed Web of Science ®Google Scholar
• Hosek, S. G., Rudy, B., Landovitz, R., Kapogiannis, B., Siberry, G., Rutledge, B., … Wilson, C. M. (2017). An HIV preexposure prophylaxis demonstration project and safety study for young MSM. JAIDS Journal of Acquired Immune Deficiency Syndromes, 74(1), 21–29. doi: 10.1097/QAI.0000000000001179
   PubMed Web of Science ®Google Scholar
• John, S. A., Whitfield, T. H. F., Rendina, H. J., Parsons, J. T., & Grov, C. (2018). Will Gay and Bisexual Men taking oral pre-exposure prophylaxis (PrEP) switch to long-acting injectable PrEP should it become available? AIDS and Behavior, 22(4), 1184–1189. doi: 10.1007/s10461-017-1907-2
   PubMed Web of Science ®Google Scholar
• Kerrigan, D., Mantsios, A., Grant, R., Markowitz, M., Defechereux, P., La Mar, M., … Murray, M. (2017). Expanding the menu of HIV prevention Options: A qualitative study of experiences with long-acting injectable cabotegravir as PrEP in the context of a phase II trial in the United States. AIDS and Behavior. doi: 10.1007/s10461-017-2017-x
   Web of Science ®Google Scholar
• Koechlin, F. M., Fonner, V. A., Dalglish, S. L., O’Reilly, K. R., Baggaley, R., Grant, R. M., … Kennedy, C. E. (2017). Values and preferences on the Use of oral Pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: A systematic review of the literature. AIDS and Behavior, 21(5), 1325–1335. doi: 10.1007/s10461-016-1627-z
   PubMed Web of Science ®Google Scholar
• Kvale, S., & Brinkman, S. (2009). Interviews: Learning the craft of qualitative research interviewing (2nd ed.). Los Angeles, CA: SAGE Publications.
   Google Scholar
• Landovitz, R. J., & Grinsztejn, B. (2016). HPTN083: A phase 2b/3 double blind safety and efficacy study of injectable cabotegravir. JHU Baltimore Washington India Clinical Trials. Retrieved from http://bwictu.jhu.edu/research/clinical-trials/hptn083
   Google Scholar
• Lansky, A., Finlayson, T., Johnson, C., Holtzman, D., Wejnert, C., Mitsch, A., … Crepaz, N. (2014). Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One, 9(5), e97596. doi: 10.1371/journal.pone.0097596
   PubMed Web of Science ®Google Scholar
• MacArthur, G. J., van Velzen, E., Palmateer, N., Kimber, J., Pharris, A., Hope, V., … Hutchinson, S. J. (2014). Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. International Journal of Drug Policy, 25(1), 34–52. doi: 10.1016/j.drugpo.2013.07.001
   PubMed Web of Science ®Google Scholar
• MacQueen, K. M., McLellan, E., Kay, K., & Milstein, B. (1998). Codebook development for team-based qualitative analysis. Field Methods, 10(2), 31–36. doi: 10.1177/1525822(980100020301
   Google Scholar
• Markowitz, M., Frank, I., Grant, R. M., Mayer, K. H., Elion, R., Goldstein, D., … Spreen, W. R. (2017). Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet HIV, 4(8), e331–e340. doi: 10.1016/S2352-3018(17)30068-1
   PubMed Web of Science ®Google Scholar
• Martin, M., Vanichseni, S., Suntharasamai, P., Sangkum, U., Mock, P. A., Chaipung, B., … Choopanya, K. (2017). Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: An observational, open-label extension of the Bangkok Tenofovir Study. The Lancet HIV, 4(2), e59–e66. doi: 10.1016/S2352-3018(16)30207-7
   PubMed Web of Science ®Google Scholar
• Martin, M., Vanichseni, S., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., … Bangkok Tenofovir Study Group. (2015). The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. Aids (london, England), 29(7), 819–824. doi: 10.1097/QAD.0000000000000613
   PubMed Web of Science ®Google Scholar
• Massachusetts Department of Public Health. (2014). Clinical Advisory: Routine screening for hepatitis C. Retrieved from http://www.mass.gov/eohhs/docs/dph/aids/hcv-clinical-advisory.pdf
   Google Scholar
• Massachusetts Department of Public Health. (2017). Clinical advisory HIV transmission through injection drug use. Retrieved from https://hmccreg3.org/wp-content/uploads/sites/90/2017/12/112707ClinicalAdvisory_HIV.pdf
   Google Scholar
• Mathers, B. M., Degenhardt, L., Ali, H., Wiessing, L., Hickman, M., Mattick, R. P., … Injecting Drug, U. (2010). HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. The Lancet, 375(9719), 1014–1028. doi: 10.1016/S0140-6736(10)60232-2
   PubMed Web of Science ®Google Scholar
• Morgan, K., Lee, J., & Sebar, B. (2015). Community health workers: A bridge to healthcare for people who inject drugs. International Journal of Drug Policy, 26(4), 380–387. doi: 10.1016/J.DRUGPO.2014.11.001
   PubMed Web of Science ®Google Scholar
• Paquette, C. E., Syvertsen, J. L., & Pollini, R. A. (2018). Stigma at every turn: Health services experiences among people who inject drugs. International Journal of Drug Policy, 57, 104–110. doi: 10.1016/j.drugpo.2018.04.004
   PubMed Web of Science ®Google Scholar
• Parsons, J. T., Rendina, H. J., Whitfield, T. H. F., & Grov, C. (2016). Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. AIDS and Behavior, 20(7), 1390–1399. doi: 10.1007/s10461-016-1370-5
   PubMed Web of Science ®Google Scholar
• Rebeiro, P., Althoff, K. N., Buchacz, K., Gill, J., Horberg, M., Krentz, H., … North American AIDS Cohort Collaboration on Research and Design. (2013). Retention among North American HIV-infected persons in clinical care, 2000–2008. Journal of Acquired Immune Deficiency Syndromes, 62(3), 356–362. doi: 10.1097/QAI.0b013e31827f578a
   PubMed Web of Science ®Google Scholar
• US Public Health Service. (2014). Preexposure prophylaxis for the prevention of HIV infection in the United States — 2014: A clinical practice guideline. Retrieved from https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf
   Google Scholar
• van Boekel, L. C., Brouwers, E. P. M., van Weeghel, J., & Garretsen, H. F. L. (2013). Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug and Alcohol Dependence, 131(1–2), 23–35. doi: 10.1016/j.drugalcdep.2013.02.018
   PubMed Web of Science ®Google Scholar